Skip to main content

Table 1 Characteristics of patients before CAR-T cell treatment

From: First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia

ID

Age/Sex

FAB subtype

Fusion gene

Gene mutation

Karyotype

History of MDS/MPN

Prior lines of treatment

Previous HSCT

Extramedullary invasion

Pre-infusion disease burden (%)

Post-infusion disease burden (%)/efficacy evaluation

Bridged HSCT

CLL-1 Positivity (%)

1

53/F

M5

Negative

KRAS、TET2、ETV6

46, XX, -7, + mar

Yes

6

No

Yes

16.43

71.78/NR

Yes

50.2

2

44/M

M2

N/A

NPM1、DNMT3A、IDH1、RUNX1、NRAS

N/A

No

8

No

No

13.47

35.42/NR

Yes

90.3

3

73/M

M5

Negative

RUNX1、CEBPA、TET2、ASXL1、NRAS

46, XY del (7), (q22q34)

Yes

2

No

No

18.49

0.23/CRi

No

82.8

4

29/M

M5

Negative

CEBPA、FLT3、TET2

N/A

No

2

No

Yes

14.50

0/CRi

Yes

92.3

5

47/F

M5

Negative

Negative

Normal

No

8

Yes

No

83.55

86.51/NR

No

89.6

6

49/F

M5

MLL-AF9

ZRSR2

N/A

No

2

No

No

28.36

0/CR

No

97.6

7

43/F

M2

Negative

Negative

N/A

No

10

Yes

No

7.12

0/CRi

No

82.2

8

39/F

M5

Negative

RUNX1, U2AF1

46, XX, + 1, der(1;7)

Yes

4

Yes

No

10.24

2.11/CRi

Yes

66.9

9

18/F

M2

Negative

RUNX1、FLT3

Normal

No

6

Yes

No

3.09

0/CRi

Yes

80.6

10

29/M

M5

Negative

Negative

Normal

No

3

Yes

No

22.80

3.02/CRi

Yes

87.6

  1. ID identification number, F female, M male, FAB French–American–British, N/A not available, MDS/MPN myelodysplastic syndrome/myeloproliferative neoplasm, HSCT hematopoietic stem cell transplantation, CR complete response, CRi CR with incomplete blood count recovery